#asco25 search results
🚨 Save the Date: Advances in Upper GI Cancer 🚨March 10, 2026 | 13:00 CET ⭐buff.ly/wkI8jEG Stay at the forefront of Upper GI oncology by joining this live, expert-led webinar highlighting the most significant and practice-changing data from: 📌 ASCO 2025 #ASCO25 📌
Join us for a 2-hour post #ASCO25 & #EHA25 @vjhemonc updates in #MDSsm of the most important abstracts delivered in abbreviated format by the authors themselves & then discussed by panels of experts. Register at Post-EHA 2025 MDS Highlights | VJHemOnc vjhemonc.com/event/post-eha…
Join Drs. Ezra Cohen, Sara Tolaney, Nataliya Uboha and Cynthia Ma for an upcoming webinar on August 12. This live discussion will explore what’s next in oncology, driven by the latest innovations shaping cancer care today. We’ll highlight breakthrough research from #ASCO25
#TumorBoardTuesday Did you all recover from #ASCO25 ❓😀 Ready for more learning❓🧑🏫 📢Join us Tuesday, 06-17-25 at 8PM ET as @lungoncdoc & @KelseyPanMD 🗣️Targeting🎯classical EGFR mutations in metastatic #NSCLC RT and bring others into the discussion‼️
As the waves 🌊 settle after #ASCO25 we @DanaFarber_GU take a deeper dive 🤿 into the most impactful data! Join @DrChoueiri @BradMcG04 @AtishChoudhury as we discuss what we learned & where we’re going next! Prostate 🔗 youtu.be/heLQLuWjlzM Bladder 🔗
🎙️ In this JAMA Medical News podcast, @KimmieNgMD, JAMA associate editor and associate chief at @DanaFarber, shares highlights from #ASCO25. 🎧 Listen now on @AMAEdHub: ja.ma/4no9Bzr
Artificial intelligence's biggest challenge in healthcare and clinical trials isn't in the technology - it's in the implementation! The optimal strategy for now is a joint human plus AI approach. See our summary of data presented #ASCO25 in #ascodailynews
Joint human and AI teams can transform cancer trial matching into a real-time, inclusive, and precise process. The key imperatives for the future are continuous auditing, responsible integration, and workforce training—making the ideal of “automatic trial matching at every visit”
After the oral presentation at #ASCO25, the OPTIMAL trial is now out in @Annals_Oncology 👉This randomized phase 3 trial showed non-inferiority of oral paclitaxel to intravenous weekly paclitaxel in HER2-negative metastatic #breastcancer doi.org/10.1016/j.anno…
At #ASCO25, research emphasized exercise, diet, and timing of immunochemotherapy as key to improving colon cancer outcomes, and called for a focus on survival and quality of life in clinical trials. 🔗 Learn more in this Medical News article: ja.ma/3Up99Uj
jamanetwork.com
Highlights From ASCO 2025
This Medical News article discusses research presented at the recent American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Patients and families facing a rare cancer diagnosis deserve timely, actionable answers. At @ASCO, Patient Advocacy Specialist Cody Barnett shared how whole genome sequencing and patient advocacy groups are helping make that possible. #ASCO25
Our 🔑 takeaways on NTRK Fusion from #ASCO25 w/ @DavidHongMD @DrJNaidoo & #TheodoreLaetsch ✅ Prevalence + Testing ✅ Rx Options ✅ AEs + Management Full 🗣️: - Oncbrothers.com/asco2025-breast - medscape.org/viewarticle/10… - Also on “Oncology Brothers” podcast #OncTwitter #CME
FDA has published in JCO the approval summary of inavolisib + palbociclib + fulvestrant (INAVO120): PFS benefit, OS trend (final OS shown at #ASCO25 but not yet FDA-reviewed), safety/tolerability incl. PROs, and companion diagnostic considerations👇 ascopubs.org/doi/10.1200/JC…
Dr. @sands_jacob reviews the data we have on Tarlatamab for patients with ES-SCLC. Important DeLLphi-304 OS data from #ASCO25 shown here. #BTGLung2025 @OncLive
Part 1/3 on SCLC! Here we discuss the treatment landscape and the data from #ASCO25 in Extensive Stage small cell w/ @HosseinBorghaei Full 📢 🌟 gotoper.com/courses/breaki… 🌟 oncbrothers.com/sclc-cme-2025-1 🌟Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #lcsm #CME
Honored to help kick off Japan Society of Clinical Oncology meeting with outstanding session reviewing important trial data from #ASCO25 annual meeting and implications for patients in the Asia Pacific region. Thx to our speakers for lending their time and expertise @ASCO
What are experts @NitinJainMD, @KrishPatelMD, & @MCThompsonMD saying about sequencing BTKi & BCL2i in CLL & the future of care with next-gen agents? Find out in our new @PeerView TownHall, recorded at #ASCO25 & featuring CLL Society. Watch now! bit.ly/3TiuzlO
In an in-depth interview with @JAMANetwork, @KimmieNgMD of @DanaFarber discusses highlights from #ASCO25, including research into lifestyle and cancer survival as well as research into the best time of day for treatment. @DFarberYoungCRC Read more here: bit.ly/3ZWNqq8
Pretty amazing run-up by $IVBXF - +135% YTD or +40% since #ASCO25 on the back of IBI363. Does today's $1.2bn up front from $TAK justify the enthusiasm?
“In a plenary, a statement that really resonated with me was that PFS doesn’t automatically mean QOL.” In our latest CancerSpeak episode, @ARosen380 shares her perspective on patient outcomes and early-onset cancer research at #ASCO25. cancerspeak.podbean.com/e/asco-2025-re… @OncoAlert
irAE ICYMI #ASCO25 recap #2: irAEs implications of ICIs 2/2 VEGF inhibitors in adv NSCLC @uvmvermont ➡️ 41 pts w/ prior ICI f/b ramucirumab ➡️ Any irAE: OS 8m vs 6m; PFS 7m vs 3m (not significant) ➡️ Delayed irAE: OS 34.5m; PFS 33.5m @KMittalMD @FunchainMD @afreenshariffmd
irAE ICYMI #ASCO25 recap #1: HBV reactivation in HCC on ICIs + antivirals @SunYatsen_Uni ➡️ 1015 HBsAg+ pts with HCC started on ICI ➡️ Reactivation risk low w/ antiviral ppx (4.5% vs 6.1%, NS) ➡️ High HBV-DNA titer not an independent OS/PFS risk
@ASPIRE_CoP 📚Since it’s April, we are rediscovering #ASCO25 sessions with a series of ICYMI recaps on immune-related adverse events (#irAEs). Short takeaways on trial design, numbers, and outcomes to keep you up to date. Stay tuned! 👇 #Oncology #Immunotherapy
After the oral presentation at #ASCO25, the OPTIMAL trial is now out in @Annals_Oncology 👉This randomized phase 3 trial showed non-inferiority of oral paclitaxel to intravenous weekly paclitaxel in HER2-negative metastatic #breastcancer doi.org/10.1016/j.anno…
Why would a $3K/year cancer treatment cost patients more than a $200K/year one? 💸 Lots of important discussion of #ChallengeTrial from #ASCO25 & why 'exercizumab' doesn't seem to be getting uptake it should. @JCOOP_ASCO @csoncol @ADetsky ascopubs.org/doi/pdf/10.120…
What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72
🎗️ #ASCO25: A New Era for Cervical Cancer At #ASCO25, Dr Domenica Lorusso highlighted exciting advances in cervical cancer treatment. Explore how these innovations are setting a new standard and offering real hope for patients. Read: touchoncology.com/insight/asco25…
I'm amazed by the progress of #bladdercancer research. I had to revise this paper after #ASCO25, #ESMO25, #GUASCO26. Thank you to @jclinicalinvest for their patience in trying to keep up with discovery. @tompowles1 @MattGalsky @AndreaNecchi @DrRosenbergMSK @UrogerliMD
🎥Aslı Doğa Munzur, BSc, discusses clonal hematopoiesis (CH) as a potential biomarker in #mCRPC ⭐Ongoing work aims to define CH’s role in predicting blood disorder risk & guiding patient selection: ➡️ow.ly/WaEt50X9GI9 @ASCO #ASCO25 #UroOnc #UroSoMe #PCSM
2025 Lung Cancer Immunotherapy Updates ✅25% pCR ✅5-yr OS with nivolumab + chemo ✅DeLLphi-304’s tarlatamab beats chemo ✅Pre-3 PM infusions boost CD8+ cells Article & Video:👉 oncologytube.com/asco-2025-lung… #Oncology #LungCancerImmunotherapy #ASCO25 @MOASC_Office @ANCO_News
“In a plenary, a statement that really resonated with me was that PFS doesn’t automatically mean QOL.” In our latest CancerSpeak episode, @ARosen380 shares her perspective on patient outcomes and early-onset cancer research at #ASCO25. cancerspeak.podbean.com/e/asco-2025-re… @OncoAlert
Vaccines are offering new hope in pancreatic cancer 💉✨ At #ASCO25, experts shared data on mRNA, peptide & allogeneic vaccines showing immune responses that may delay recurrence. Read here specialtypharmacycontinuum.com/a/GzIBAA/t #PancreaticCancer #Oncology
📢 #ASCO25: Expanding Access to CAR T-Cell Therapy CAR T-cell therapies are transforming outcomes for patients with advanced blood cancers, yet only 2–3 in 10 eligible patients currently receive treatment. At ASCO 2025, the CAR T Vision Coalition was unveiled, aiming to double
Congratulations @OrlaCashman on presenting at #ASCO25
Major imposter syndrome presenting my poster at #ASTRO2025 😅 Huge thanks to @CUH_Cork for all the support. Thrilled to share our work on SGRT & liver SBRT. Proud to represent RTs and show the value we bring and flying the flag for Cork! 🔴⚪️ #SGRT #liverSBRT @VisionRTLtd
$MRUS #ASCO25 data were a major validation, but this is still a high-risk bet on ph3. I guess some time next year we find out whether this is $GMAB $8bn well spent.
🎥Jason Mouabbi, MD, shares an overview of key studies in breast cancer presented at #ASCO25: ➡️ow.ly/AX2750X38gy⬅️ @ASCO #CTSM #TrialUpdate #ImmunoOnc #BreastCancer #BCSM
Hearing from @thenasheffect at the @OUHealth-hosted #BestOfASCO In Oklahoma City! Some great topics! My favorite is on the #TcellEngagers! @ASCO #ASCO25
Hearing from @TiansterZhang of @utswcancer presented at @OUHealth’s hosted #BestofASCO here in Oklahoma City! Amazing review of all of the best #GUonc data from @ASCO this year!! #ASCO25
🎥@MichaelGnant from @MedUni_Wien reviews long-term endocrine therapy in HR+ breast cancer: benefit for high-risk pts, ovarian suppression in ASTRRA, & elinzanetant for vasomotor symptoms: Watch here➡️ ow.ly/6gZh50X36A4 @ASCO #ASCO25 #BCSM #BreastCancer #CTSM #TrialUpdate
This was a great panel at #ASCO25! Thank you @imdat_eroglu for highlighting it in #ASCOConnection and I’m glad you left feeling empowered!
A session during #ASCO25 shifted my perspective about advocacy completely. Check out my piece on #ASCOconnection Advocacy Starts With Us: What I Learned About Advocacy at ASCO25 | ASCO Connection connection.asco.org/do/advocacy-st… @ASCO @JasmineKambojMD @christeeny513 @ASCOTECAG
Dr. @EladSharonMD giving updates on GI onc from #ASCO25 at best of @ASCO Oklahoma Society of Clinical Oncology: E/GEJC with the lion's share of periop IO, ADCs, and CAR T.
Join Drs. Ezra Cohen, Sara Tolaney, Nataliya Uboha and Cynthia Ma for an upcoming webinar on August 12. This live discussion will explore what’s next in oncology, driven by the latest innovations shaping cancer care today. We’ll highlight breakthrough research from #ASCO25
Perhaps our most important publication in public health related to cancer this year. Led by @Jani_Chinmay - our chief fellow and soon to be colleague @SylvesterCancer This was his oral presentation at #ASCO25 @ASCO and got a lot of interest Alcohol-related cancer deaths are
Honored to help kick off Japan Society of Clinical Oncology meeting with outstanding session reviewing important trial data from #ASCO25 annual meeting and implications for patients in the Asia Pacific region. Thx to our speakers for lending their time and expertise @ASCO
Great discussions and questions at the panel debate on the #ASCO25 Review at @OhioStateMedOnc @lingbin_meng @AsrarAlahmadi @LoganRoofMD @HasanovLab @DCarboneMD @AshishManne @OSUCCC_James
💫Missed @ASCOTECAG #Trainee & Early Career #Oncologist Lounge sessions #ASCO25? We turned key panels into editorials so everyone can easily access expert professional development insights! 🔶Series overview tinyurl.com/5n6vutrb by @NazliDizman @ASCO #MedEd #ASCO26 @ASCOPres
🔥📣The 2025 #ASCOEdBook collection from @ASCO #ASCO25 is now complete & fully available (for free). ✅It’s a great resource with very EDUCATIONAL peer-reviewed articles by great experts. Outstanding job by editors & authors.👏 Link to full edition👇🏻 bit.ly/44bvEkk
#TumorBoardTuesday Did you all recover from #ASCO25 ❓😀 Ready for more learning❓🧑🏫 📢Join us Tuesday, 06-17-25 at 8PM ET as @lungoncdoc & @KelseyPanMD 🗣️Targeting🎯classical EGFR mutations in metastatic #NSCLC RT and bring others into the discussion‼️
After the oral presentation at #ASCO25, the OPTIMAL trial is now out in @Annals_Oncology 👉This randomized phase 3 trial showed non-inferiority of oral paclitaxel to intravenous weekly paclitaxel in HER2-negative metastatic #breastcancer doi.org/10.1016/j.anno…
MATTERHORN #ESMO25 – LBA81 Durvalumab + FLOT becomes the first peri-operative immunotherapy regimen to show an overall survival benefit in resectable gastric/GEJ cancer. Viewed alongside the #ASCO25 interim (EFS, pCR) results, the final OS data complete the picture —
As the waves 🌊 settle after #ASCO25 we @DanaFarber_GU take a deeper dive 🤿 into the most impactful data! Join @DrChoueiri @BradMcG04 @AtishChoudhury as we discuss what we learned & where we’re going next! Prostate 🔗 youtu.be/heLQLuWjlzM Bladder 🔗
Exercizumab is real. Aerobic exercise cut colon cancer recurrence + death. It’s time to combine movement with medicine not one or the other. #oncology #Cancer @NEJM @OncoAlert @ASCO #ASCO25 DOI: 10.1056/NEJMoa2502760
Delighted to present path response from our Neoadjuvant ImmunoRadioTherapy (NIRT-2) trial in pts w HPV- HNSCC @ASCO mPR=71% pCR=29% Downstaging=67% Omission of adjuvant RT=83% Surgical de-escalation=50% @ChilesResearch @UCSDCancer_COE @CalifanoMd #ASCO25 meetings.asco.org/abstracts-pres…
Dr. @sands_jacob reviews the data we have on Tarlatamab for patients with ES-SCLC. Important DeLLphi-304 OS data from #ASCO25 shown here. #BTGLung2025 @OncLive
⭐️The highlight of @ASCO #ASCO25 👉🏼A fantastic Greek dinner thanks to the amazing @PGrivasMDPhD ! It all started with the great #BaklavaWars -an arm flex match over its true origin 1/2 @OncoAlert @neerajaiims
The DESTINY-Gastric04 trial, presented at #ASCO25, established T-DXd as a preferred second-line treatment option for HER2+ metastatic gastric cancer/GEJA. For #ASCODailyNews, @KoheiShitara & Dr. Izuma Nakayama evaluate these important findings: brnw.ch/21wUdDp
#TumorBoardTuesday 😮We had a rare #ASCO25 with several key🗝️updates in #PancreaticCancer So to put this in context: 📢Join us Tuesday, 07-08-25 at 8PM ET as @DrShubhamPant & @DanielHaldarMD 🗣️Optimizing 1L Treatment Selection in mPDAC RT and bring others into the discussion‼️
🎙️ @shaalanbeg and @KristenCiombor of @VUMC highlight practice-changing abstracts across GI cancers from #ASCO25 on the #ASCODailyNews Podcast: bit.ly/3ZNXK3H #gicsm #OncTwitter
🩸 Potential new standard of care in newly diagnosed #MultipleMyeloma ADVANCE trial from #ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients. 👨⚕️ @DrOlaLandgren #YearInReview 🔗 ascopost.com/news/june-2025…
Dr. @BRicciutiMD of @DFarberThoracic discusses emerging biomarkers in the periop setting of #nsclc . Clip courtesy of @NarjustFlorezMD . @ASCO #ASCO25 #lcsm #lcam
Something went wrong.
Something went wrong.
United States Trends
- 1. #euphoria N/A
- 2. #WrestleMania N/A
- 3. Roman N/A
- 4. Wemby N/A
- 5. Buffalo N/A
- 6. Night 2 N/A
- 7. Bruins N/A
- 8. Spurs N/A
- 9. Tage Thompson N/A
- 10. Rhea N/A
- 11. #TusksUp N/A
- 12. #PorVida N/A
- 13. #BaddiesUSAReunion N/A
- 14. Pistons N/A
- 15. Summerslam N/A
- 16. Swayman N/A
- 17. Sam Levinson N/A
- 18. Cade N/A
- 19. Maddy N/A
- 20. Brock N/A